Navigation Links
Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer

RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of Christopher H. Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer. Cabell succeeds Oren Cohen, M.D., who was recently appointed Senior Vice President, Clinical Research Strategies.

As Chief Medical and Scientific Officer, Cabell will be responsible for company-wide initiatives that focus on bioethics and the protection of human subjects. In addition, he will be responsible for developing initiatives that bring forward innovations in medicine, science and technology into future business models.

Most recently, Cabell held the position of Global Cardiovascular / Endocrine Therapeutic Group Leader within the Medical and Scientific Services group and provided cardiology expertise for Quintiles Electrocardiogram (ECG) Services. In 2007, Cabell joined Quintiles from the Duke University School of Medicine, where he developed a strong background in clinical research. He held several appointments within the Duke Clinical Research Institute (DCRI), including Co-Chair and Principal Investigator for a Duke/FDA Cardiac Safety partnership to develop a new generation of tools to identify the potential effects of medical devices and drugs on the heart. Also within DCRI, he held appointments as Director of the Echocardiography Core Laboratory, Associate Director of the ECG Core Laboratory and Director of the International Collaboration on Endocarditis. He also was Assistant Professor of Medicine in the Division of Cardiology.

Cabell has authored or co-authored 50 articles for peer-reviewed publications and delivered more than 30 invited lectures. He is a member of several professional organizations, a Fellow of the American College of Cardiology, and a reviewer for a number of medical journals, including the Journal of the American Medical Association. He earned his medical degree and a Master's in Health Science from the Duke University School of Medicine.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at

SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Expert Cardiologist Joins Quintiles Medical Group
3. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
4. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
5. Quintiles to Open Clinical Research Office in Wilmington, NC
6. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
7. Quintiles Consulting Business Expands
8. Quintiles Signs Agreement to Acquire Eidetics
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):